Lebrikizumab Phase 3 Trials: ADvocate1 and ADvocate2 for Atopic Dermatitis

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Lebrikizumab Phase 3 Trials: ADvocate1 and ADvocate2 for Atopic Dermatitis

By Raj Chovatiya 5 Videos

467 views

October 26, 2023

Disclaimer: On September 13, 2024, the U.S. Food and Drug Administration (FDA) approved EBGLYSS™ (lebrikizumab-lbkz), ...
read more ↘ a targeted IL-13 inhibitor, for the treatment of adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis (eczema) that is not well controlled despite treatment with topical prescription therapies.
↖ read less

Comments 0